| Literature DB >> 30364319 |
Lindsay Young1, Jennifer Gadient1, Cora Lind1.
Abstract
The high pressure behavior of negative thermal expansion materials continues to be of interest, as their potential use in controlled thermal expansion composites can be affected by irreversible pressure-induced phase transitions. To date, it is not possible to predict the high pressure behavior of these compounds, necessitating measurements on each composition. In this work, high pressure synchrotron powder X-ray diffraction studies of Cr2Mo3O12 and Y2Mo3O12 were conducted in a diamond anvil cell. Chromium molybdate, which adopts the monoclinic P21/a structure under ambient conditions, was found to not undergo any crystalline-crystalline transitions up to 8.9 GPa. The orthorhombic ambient pressure polymorph of yttrium molybdate was found to undergo a phase transition to the monoclinic P21/a scandium tungstate structure below 0.13 GPa. This structure is frequently observed for related materials at low temperatures, but has never been reported for Y2Mo3O12. No additional changes in this material were observed up to 4.9 GPa. The fact that the monoclinic polymorphs of these materials do not undergo phase transitions within the studied pressure range makes them unique among A2M3O12 materials, as most isostructural compositions undergo at least one phase transition to crystalline high pressure phases.Entities:
Keywords: high pressure; in-situ studies; negative thermal expansion; scandium tungstate family; synchrotron radiation
Year: 2018 PMID: 30364319 PMCID: PMC6193095 DOI: 10.3389/fchem.2018.00478
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Current high pressure research on scandium tungstate family materials.
| AlFeMo3O12 | PXRD (Young et al., | M:E | 1.7 | α' transition from isotropic to anisotropic compression | R |
| 3.2 | P21/a γ-phase a = 14.94 Å, b = 8.71 Å, c = 17.48 Å, β = 124.4° | R | |||
| 3.9-4.2 | Monoclinic δ-phase, a = 14.20 Å, b = 8.36 Å, c = 13.57 Å, β = 102.0° | R, H | |||
| AlGaMo3O12 | PXRD (Young et al., | M:E | 2.0, 2.9 | α' and α” transition from isotropic to anisotropic compression | R |
| 4.1–4.4 | P21/a γ-phase a = 14.76 Å, b = 8.59 Å, c = 17.21 Å, β = 124.6° | R | |||
| 5.0–5.3 | Monoclinic δ-phase a = 14.16 Å, b = 8.32 Å, c = 13.62 Å, β = 102.2° | R, H | |||
| Al2Mo3O12 | PXRD (Young et al., | M:E | 3.0 | α' transition from isotropic to anisotropic compression | R |
| 4.6–4.9 | P21/a γ-phase a = 14.65 Å, b = 8.53 Å, c = 17.08 Å, β = 124.5° | R | |||
| 5.7–6.1 | Monoclinic δ phase a = 14.04 Å, b = 8.28 Å, c = 13.47 Å, β = 101.9° | R, H | |||
| Al2W3O12 | Raman (Garg et al., | M:E | 0.05 | Unindexed phase | R < 2 |
| 7 | Amorphization | I | |||
| PXRD (Achary et al., | None | 8, 48 h | ambient phase recovered | ||
| PXRD/900°C (Achary et al., | None | 3 | Decomposes to AlWO4 + WO3−x | ||
| AC resistivity (Mukherjee et al., | None | 0.5 | Phase transition | I | |
| Raman (Maczka et al., | M:E | 0.28 | Potentially monoclinic | R | |
| 2.8 | Unindexed | ||||
| PXRD/ dielectric measurement (Mukherjee et al., | M:E | 0.5 | P 21 a = 8.95 Å, b = 9.07 Å, c = 12.59 Å, β = 90.51° | ND | |
| 3.4 | P 21 a = 9.59 Å, b = 12.52 Å, c = 7.84 Å, β = 91.99° | ND | |||
| 6–18 | Amorphization | I | |||
| Raman (Garg et al., | M:E | 0.4–3 | Unindexed phase | R | |
| 5.3–6 | Unindexed phase | ND | |||
| 14 | Amorphization | I | |||
| PXRD (Varga et al., | iPrOH | 0.1 | P21/a a = 15.41 Å, b = 9.05 Å, c = 19.91 Å, β = 125.4° | R | |
| 7 | Amorphization | I | |||
| Fe2Mo3O12 | PXRD (Young et al., | M:E | 1.5 | α' transition from isotropic to anisotropic compression | R |
| 2.7–2.9 | P21/a γ-phase a = 15.06 Å, b = 8.79 Å, c = 17.63 Å, β = 124.6° | R | |||
| 3.5–3.7 | Monoclinic δ phase a = 14.46 Å, b = 8.48 Å, c = 13.77 Å, β = 102.0° | R, H | |||
| Raman (Moura et al., | Mineral oil | 4.8 | Amorpization | R | |
| Ga2Mo3O12 | PXRD (Gates et al., | M:E | 3.2 | Monoclinic phase a = 13.7 Å, b = 7.3 Å, c = 12.3 Å, β = 115.9° | R |
| 4.2 | a = 14.4 Å, b = 8.3 Å, c = 13.8 Å, β = 103.1° | R | |||
| 8 | Amorphization | I | |||
| PXRD (Young et al., | M:E | <3.3 | P21/a γ-phase a = 15.24 Å, b = 8.68 Å, c = 17.44 Å, β = 126.1° | ||
| <4.2 | Monoclinic δ-phase a = 14.45 Å, b = 8.34 Å, c = 13.71 Å, β = 101.3° | ||||
| In2Mo3O12 | Raman (Mendonça et al., | M:E | 1.5 | Denser structure | ND |
| 5–>7 | Gradual amorphization | I | |||
| In1.5Y0.5Mo3O12 | Raman (Mendonça et al., | M:E | 1.0 | Denser structure | ND |
| 3.4–5 | Two stage amorphization | ND | |||
| In2W3O12 | PXRD (Baiz, | M:E | 1.9–2.7 | a = 19.68 Å, b = 4.49 Å, c = 17.34 Å, b = 99.21° | ND |
| >2.7 | Progressive amorphization | I | |||
| Lu2W3O12 | PXRD (Liu et al., | None | 5–8 | Progressive amorphization | I |
| Sc2Mo3O12 | PXRD and Raman (Arora et al., | M:E | 4–12 | Two stage amorphization; distortions and disordering at 4 GPa, complete at 12 GPa | I |
| PXRD and Raman (Paraguassu et al., | M:E Raman | 0.29 | Unknown potentially monoclinic phase ( | R | |
| 2.7 | Unknown phase | R | |||
| 3.7–5.1 | Amorphization | R < 5 | |||
| 16:3:1 M:E:H(PXRD) | 4–20 | Amorphization | I after compression to 20 | ||
| PXRD and Raman (Arora et al., | M:E | 12 | Amorphization | I | |
| PXRD (Varga et al., | iPrOH | 0.25 | P21/a a = 16.51 Å, b = 9.54 Å, c = 18.84 Å, β = 125.35° | ND | |
| 2.5–3.0 | Unknown phase | ND | |||
| 8 | Amorphization | Mostly I | |||
| Sc2W3O12 | Raman (Garg et al., | M:E | 0.45 | Unindexed | R |
| 7 | Amorphous | I | |||
| PXRD (Secco et al., | None | 8 | Amorphous | I | |
| PXRD/400°C (Secco et al., | None | 3.2 | Unindexed | ND | |
| 4 | Amorphous | I | |||
| PXRD/Raman (Garg et al., | M:E | 0.6 | a = 16.0 Å, b = 9.4 Å, c = 18.6 Å, β = 124.9° | R | |
| 1.6 | a = 13.81 Å, b = 9.6 Å, c = 18.26 Å, β = 123.91° | I | |||
| 6.5–14 | Amorphous | I | |||
| PXRD (Varga et al., | iPrOH, N2 | 0.3 | a = 16.25 Å, b = 9.58 Å, c = 18.94 Å, β = 125.4° | R | |
| 2.8 | Unindexed | I | |||
| ND (Varga et al., | He | 0.25–0.3 | a = 16.25 Å, b = 9.58 Å, c = 18.93 Å, β = 125.37° | H | |
| PXRD (Cetinkol et al., | M:E | 0.3 | a = 16.25 Å, b = 9.58 Å, c = 18.93 Å, β = 125.38° | ||
| M:E | 2.7 | a = 8.45 Å, b = 11.31 Å, c = 9.15 Å, α = 96.6° | I | ||
| Pbcn -Y2Mo3O12 | Raman (Torres Dias et al., | Mineral Oil | 0.3 | Potentially monoclinic, 0.3 GPa | ND |
| 2.4 | Amorphization, 2.4 GPa | I | |||
| Y2W3O12 | PXRD, Raman (Karmakar et al., | M:E | >3 | Progressive amorphization | I > 4 |
| Zr2W2PO12 | PXRD (Cetinkol et al., | M:E | 1.37 | a = 9.30 Å, b = 12.10 Å, c = 9.05 Å, β = 89.60°, P21/n11 | R |
| >3 | a = 9.34 Å, b = 11.40 Å, c = 8.21 Å, β = 97.37° P21/n11 | R | |||
| >6.3 | a = 11.15 Å, b = 9.38 Å, c = 12.52 Å, α = 88.87°, β = 141.65°, γ = 90.93° | R | |||
| >14 | Partial amorphization | I |
M:E, 4:1 Methanol:Ethanol; M:E:H, 16:3:1 Methanol:Ethanol:Water.
In the final column, I, irreversible, R, reversible, H, hysteresis, and ND, not determined.
Figure 1Yttrium molybdate (A) trihydrate formed upon exposure to atmospheric moisture, (B) Pbcn polymorph reformed after drying.
Figure 2(A,B) Stacked 2D overlays of all high pressure data and (C) selected patterns for Cr2Mo3O12 collected during compression unless stated otherwise. In (C), NaCl peaks are indicated by * in the pattern collected after decompression, and the strongest peak of the unidentified impurity phase is marked with an arrow. Vertical arrows in (B) mark peaks that broaden significantly compared to other Cr2Mo3O12 peaks, while the horizontal arrow indicates an area of peak coalescence.
Figure 3(A) Stacked 2D overlay of all high pressure data and (B) selected patterns for Pbcn-Y2Mo3O12 collected during compression and after decompression. In (B), NaCl peaks are indicated by * in the pattern collected after decompression.
Figure 4Rietveld plots of Cr2Mo3O12 data collected at (A) 0.05 GPa and (B) 3.7 GPa refined using the P21/a structure.
Figure 5Relative compressibility of Cr2Mo3O12, (A) cell axes and (B) volume. The hydrostatic limit is indicated by a vertical line.
Figure 6Rietveld plots of PXRD data collected at 0.13 GPa refined using structural models in space groups (A) Pbcn and (B) P21/a. * indicates peaks that cannot be accounted for by the orthorhombic cell.
Atomic coordinates for monoclinic Y2Mo3O12 at 0.13 GPa (space group P21/a).
| Y1 | 0.37 (5) | 0.96 (5) | 0.32 (2) |
| Y2 | 0.38 (5) | 0.46 (5) | 0.05 (3) |
| Y3 | 0.13 (3) | 0.48 (5) | 0.18 (2) |
| Y4 | 0.11 (5) | 0.97 (5) | 0.43 (4) |
| Mo1 | −0.01 (3) | 0.25 (4) | 0.49 (3) |
| Mo2 | 0.37 (4) | 0.13 (3) | 0.14 (2) |
| Mo3 | 0.13 (3) | 0.14 (5) | 0.26 (2) |
| Mo4 | 0.14 (3) | 0.61 (4) | 0.37 (2) |
| Mo5 | 0.35 (3) | 0.64 (4) | 0.20 (2) |
| Mo6 | −0.02 (3) | 0.72 (5) | 0.01 (2) |
| O1 | 0.58 (19) | 0.40 (20) | 0.00 (11) |
| O2 | 0.00 (20) | 0.43 (18) | 0.16 (9) |
| O3 | 0.90 (13) | 0.20 (20) | 0.10 (12) |
| O4 | 0.74 (18) | 0.43 (13) | 0.06 (12) |
| O5 | 0.52 (16) | 0.37 (17) | 0.14 (12) |
| O6 | 0.70 (20) | 0.46 (16) | 0.29 (10) |
| O7 | 0.46 (14) | 0.12 (17) | 0.40 (13) |
| O8 | 0.18 (15) | 0.30 (20) | 0.26 (11) |
| O9 | 0.57 (16) | 0.40 (20) | 0.47 (10) |
| O10 | 0.42 (12) | 0.30 (20) | 0.98 (13) |
| O11 | 0.12 (11) | 0.38 (17) | 0.08 (12) |
| O12 | 0.40 (20) | 0.38 (16) | 0.49 (11) |
| O13 | 0.87 (14) | 0.39 (16) | 0.23 (13) |
| O14 | 0.25 (17) | 0.01 (19) | 0.54 (12) |
| O15 | 0.15 (13) | 0.04 (16) | 0.35 (12) |
| O16 | 0.50 (20) | 0.95 (17) | 0.34 (10) |
| O17 | 0.70 (20) | 0.97 (19) | 0.16 (12) |
| O18 | 0.65 (15) | 0.89 (14) | 0.28 (9) |
| O19 | 0.97 (12) | 0.93 (14) | 0.30 (9) |
| O20 | 0.04 (12) | 0.32 (18) | 0.60 (10) |
| O21 | 0.11 (14) | 0.80 (20) | 0.36 (12) |
| O22 | 0.06 (17) | 0.66 (19) | 0.13 (13) |
| O23 | 0.37 (15) | 0.61 (17) | 0.12 (9) |
| O24 | 0.31 (12) | 0.80 (20) | 0.22 (9) |
Figure 7Relative compressibility of monoclinic Y2Mo3O12, (A) cell axes and (B) volume. The hydrostatic limit is indicated by a vertical line.